Sugi Predict

Sugi Predict / Compounds / SCHEMBL335743

SCHEMBL335743

SCHEMBL335743

Cc1cc(C=O)cnc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ PTGER4 P35408 1/20 0.34
▸ ALDH1A3 P47895 2/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ AGBL2 Q5U5Z8 1/20 0.33
▸ KCNJ1 P48048 1/20 0.32
▸ PIK3CA P42336 1/20 0.31
▸ METAP2 P50579 1/20 0.31
▸ FDPS P14324 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ MAOA P21397 2/20 0.30
▸ MAOB P27338 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16623137 0.79 TP53 (0.33) AGBL2PTGS1PTGS2
SCHEMBL30013048 0.78 ALDH1A1 (0.37) ALDH1A1L3MBTL1PTGER4KCNJ1GAA
SCHEMBL29954177 0.78 ALDH1A1 (0.37) ALDH1A1L3MBTL1PTGER4KCNJ1GAA
SCHEMBL335598 0.78 ALDH1A1 (0.39) SRCALDH1A1KDM4EPTGER4ALDH1A3
SCHEMBL30590409 0.78 ALDH1A1 (0.39) SRCALDH1A1KDM4EPTGER4ALDH1A3
SCHEMBL14967134 0.78 ALDH1A1 (0.37) ALDH1A1L3MBTL1KDM4ECYP2A6KCNJ1
SCHEMBL29951110 0.77 SRC (0.36) SRCALDH1A1KDM4EPTGER4ALDH1A3
SCHEMBL336270 0.76 ALDH1A1 (0.37) SRCALDH1A1L3MBTL1KDM4EPTGER4
SCHEMBL7992585 0.75 ALDH1A1 (0.43) ALDH1A1L3MBTL1PTGER4ALDH1A3KCNJ1
SCHEMBL7981808 0.75 ALDH1A3 (0.37) ALDH1A1L3MBTL1PTGER4ALDH1A3KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4178620-B1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-01 — — EP disclosed
US-12528786-B2 Plasma kallikrein inhibitors MERCK SHARP & DOHME LLC (US) 2026-01-20 — — US disclosed
US-20250304596-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
US-20250276074-A1 BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF PRELUDE THERAPEUTICS INCORPORATED 2025-09-04 — — US disclosed
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 — — US disclosed
EP-4522277-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 — — US disclosed
CN-117295726-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2023-12-26 — — CN disclosed
WO-2023220137-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
US-20230348428-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-02 — — US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 — — US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 — — US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 — — US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 — — EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 — — WO disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 — — WO disclosed
EP-2300476-B1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LTD (GB) 2014-01-08 — — EP disclosed
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 — — EP disclosed
US-8097628-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-01-17 — — US disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114374-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L10 SRC 3321/4885ALDH1A1 3831/4885L3MBTL1 317/4885
US-20230348428-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, SERPINE1, KLK5 SRC 3643/4885ALDH1A1 1683/4885L3MBTL1 4262/4885
US-20240199587-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP4B1 SRC 4344/4885ALDH1A1 295/4885L3MBTL1 2757/4885
US-12528786-B2 Plasma kallikrein inhibitors CFH, KLKB1, SERPINH1 SRC 3022/4885ALDH1A1 3480/4885L3MBTL1 1922/4885
US-20090306089-A1 COMPOUNDS SDHA, NQO1, SDHB SRC 3421/4885ALDH1A1 612/4885L3MBTL1 4667/4885
US-20250304596-A1 PYRAZINE DERIVATIVES AND USES THEREOF VHL, BRCA1, SF3B5 SRC 1904/4885ALDH1A1 1908/4885L3MBTL1 3922/4885
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 SRC 3999/4885ALDH1A1 558/4885L3MBTL1 3956/4885
US-20250276074-A1 BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF CRBN, RBX1, SMARCE1 SRC 1553/4885ALDH1A1 1678/4885L3MBTL1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.